ENLIVEN THERAPEUTICS INC (ELVN) Stock Analyst Earnings Estimates
NASDAQ:ELVN - Nasdaq - US29337E1029 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 87,527.45% | N/A 1,450.23% | N/A 129.89% | N/A 95.84% | N/A 54.39% | ||||||||
| EBITDA YoY % growth | N/A | -10.68M | -24.09M -125.56% | -41.6M -72.69% | -51.34M -23.41% | -33.66M 34.44% | -83.232M -147.27% | N/A -29.48% | N/A -35.82% | N/A -42.83% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -8.91M | -10.68M -19.87% | -24.12M -125.84% | -41.7M -72.89% | -51.44M -23.36% | -34.27M 33.38% | -83.529M -143.74% | N/A -29.87% | N/A -23.91% | N/A -23.80% | N/A -15.48% | N/A -6.92% | N/A -4.12% | N/A 70.97% | N/A 732.38% | N/A 85.90% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -6.18 | -3.99 35.44% | N/A 63.24% | -2.19 -49.31% | N/A 9.24% | N/A -20.60% | N/A -14.12% | N/A -21.19% | N/A -7.69% | N/A 88.86% | N/A 576.92% | N/A 109.68% | N/A 72.82% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.53 -12.23% | -0.59 -8.61% | -0.61 -48.02% | -0.69 -43.44% | -0.61 -16.02% |
| Revenue Q2Q % growth | N/A | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -29.25M -28.69% | -31.977M -23.05% | -32.844M -33.50% | -36.516M -34.90% | -36.006M -23.10% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.48 5.88% | -0.51 | 0.03 | 5.29% |
| Q2 2024 Q2Q % growth | -0.41 | -0.56 | 0.15 | 27.01% |
| Q1 2024 Q2Q % growth | -0.54 32.50% | -0.58 | 0.04 | 6.74% |
| Q4 2023 Q2Q % growth | -0.47 -135.09% | -0.55 | 0.08 | 14.67% |
| Q3 2023 Q2Q % growth | -0.51 29.17% | -0.48 | -0.03 | -5.82% |
| Q2 2023 Q2Q % growth | -0.41 76.70% | -0.37 | -0.04 | -11.97% |
| Q1 2023 Q2Q % growth | -0.80 64.29% | -0.65 | -0.15 | -23.84% |
| Q4 2022 Q2Q % growth | 90.57% | -0.20 | % | |
| Q3 2022 Q2Q % growth | -0.72 -30.91% | -1.02 | 0.30 | 29.41% |
| Q2 2022 Q2Q % growth | -1.76 -137.84% | -2.09 | 0.33 | 15.75% |
| Q1 2022 Q2Q % growth | -2.24 -286.21% | -2.36 | 0.12 | 5.01% |
| Q4 2021 Q2Q % growth | -2.12 -278.57% | -3.06 | 0.94 | 30.81% |
| Q3 2021 Q2Q % growth | -0.55 23.61% | -0.86 | 0.31 | 36.24% |
| Q2 2021 Q2Q % growth | -0.74 -25.42% | -0.82 | 0.08 | 9.43% |
| Q1 2021 Q2Q % growth | -0.58 86.54% | -0.85 | 0.27 | 31.90% |
| Q4 2020 Q2Q % growth | -0.56 | -0.85 | 0.29 | 34.48% |
| Q3 2020 Q2Q % growth | -0.72 | -0.82 | 0.10 | 11.91% |
| Q2 2020 Q2Q % growth | -0.59 | -0.57 | -0.02 | -2.92% |
| Q1 2020 Q2Q % growth | -4.31 | -0.75 | -3.56 | -474.90% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 1.09% | 2.69% | 0% | -0.94% |
| Revenue | N/A | N/A | N/A | N/A |